Cancer Research UK
Xenograft response to cisplatin can occur regardless of p53 status
Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
"We examined the cellular and molecular consequences of cisplatin treatment using two ovarian tumor xenograft models that had not been previously adapted to culture in vitro. Both xenografts were curable with clinically relevant multiple doses of cisplatin," reported Cancer Research UK scientist P.A. Clarke and colleagues.
"Following a single dose of cisplatin (6 mg/kg i.p.) growth delays of 25 and 75 days were obtained for pxn100 and pxn65, respectively," they said, noting that the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Acambis plc
Pharma company releases third quarter 2004 results - Access Pharmaceuticals, Inc.
Pharmaceutical company reports loss of $0.16 per share - Alchemia Limited
Pharma company discusses financial results - Amgen, Inc.
Biotech company announces offer of $2B in two series of senior notes - Antares Pharma, Inc.
Pharmaceutical firm reports loss of $0.06 per share - Astralis, Ltd.
Biotech company reports loss of $0.02 per share - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
